专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2004235794A1 Tamper resistant transdermal dosage form comprising an active agent componenet and an adverse agent component at the distal site of the active agent layer 未知
公开(公告)号：AU2004235794A1
公开(公告)日：2004-11-18
申请号：AU2004235794
申请日：2004-04-30
申请人： PURDUE PHARMA LP , STEPHEN HOWARD , REIDENBERG BRUCE
发明人： HOWARD STEPHEN A , REIDENBERG BRUCE
IPC分类号： A61K9/00 , A61K9/70 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.

2. 发明公开

EP1641441A2 TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER 有权转让
标题翻译：操控安全透皮药剂含有活性成分和组成部分主动层的远端点
公开(公告)号：EP1641441A2
公开(公告)日：2006-04-05
申请号：EP04751268.6
申请日：2004-04-30
申请人： Purdue Pharma Ltd. , Howard, Stephen, A. , Reidenberg, Bruce
发明人： HOWARD, Stephen, A. , REIDENBERG, Bruce
IPC分类号： A61K9/70 , A61K31/4468 , A61K31/485 , A61K9/00
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.

3. 发明申请

WO2005007218A8 EX VIVO PERFUSION 审中-公开
公开(公告)号：WO2005007218A8
公开(公告)日：2010-02-25
申请号：PCT/US2004022249
申请日：2004-07-09
申请人： EURO CELTIQUE SA , REIDENBERG BRUCE E , BURCH RONALD M
发明人： REIDENBERG BRUCE E , BURCH RONALD M
IPC分类号： A61M20060101 , A61M1/36
CPC分类号： A61M1/3679
摘要： A method of removing a target molecule from blood by contacting the blood with an ex vivo perfusion device comprising binding partners for the target molecule is provided. The ex vivo perfusion device preferably comprises one or more immobilized synthebodies as binding partners. Also provided is a method for treating a patient suffering from symptoms associated with an adenoma or other endocrine tumor. The method comprises contacting the blood or a blood component of the patient with an ex vivo perfusion device to which one or more binding partners of a hormone secreted by the tumor are immobilized. The tumor can be, for example, an insulinoma or a parathyroid hormone (PTH) adenoma, and the hormone can be, for example, insulin, PTH, glucagon, VIP, and somatostatin. The binding partner can be, e.g., a synthebody or a part thereof.
摘要翻译：提供了通过使血液与包含靶分子的结合配偶体的离体灌注装置接触来从血液中除去靶分子的方法。离体灌注装置优选包含一个或多个固定化合成物作为结合配偶体。还提供了治疗患有与腺瘤或其他内分泌肿瘤相关的症状的患者的方法。该方法包括使患者的血液或血液成分与体外灌注装置接触，所述离体灌注装置固定有一种或多种由肿瘤分泌的激素的结合配偶体。肿瘤可以是例如胰岛素瘤或甲状旁腺激素（PTH）腺瘤，并且该激素可以是例如胰岛素，PTH，胰高血糖素，VIP和生长抑素。结合配偶体可以是例如合成物或其一部分。

4. 发明申请

WO2005011578A3 PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN 审中-公开
标题翻译：术后疼痛的术前治疗
公开(公告)号：WO2005011578A3
公开(公告)日：2005-09-09
申请号：PCT/US2004024009
申请日：2004-07-26
申请人： EURO CELTIQUE SA , REIDENBERG BRUCE E , SPYKER DANIEL A
发明人： REIDENBERG BRUCE E , SPYKER DANIEL A
IPC分类号： A61F13/00 , A61K20060101 , A61K9/70 , A61K31/485
CPC分类号： A61K9/0014 , A61K9/7023 , A61K31/485
摘要： A method of treating postoperative pain in a patient undergoing a surgery id described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain.
摘要翻译：一种治疗正在进行所描述的手术的患者的术后疼痛的方法。该方法基于术前给予含有丁丙诺啡的透皮剂型。例如，可以在手术前1-4天给患者施用剂型。本发明的替代实施方案包括后续的透皮剂型以治疗术后疼痛。

5. 发明申请

WO02070524A2 N-BUT-3-ENYL NORBUPRENORPHINE AND ITS USE AS ANALGESIC 审中-公开
标题翻译： N-BUT-3-ENYL NORBUPRENPHENPHINE及其用作镇痛药
公开(公告)号：WO02070524A2
公开(公告)日：2002-09-12
申请号：PCT/US0206766
申请日：2002-03-04
申请人： PURDUE PHARMA LP , REIDENBERG BRUCE E , GALE DONNA-DONIGI , SRINIVASAN VINAYAK J
发明人： REIDENBERG BRUCE E , GALE DONNA-DONIGI , SRINIVASAN VINAYAK J
IPC分类号： A61K9/08 , A61K9/10 , A61K9/14 , A61K9/19 , A61K9/20 , A61K9/48 , A61K31/485 , A61P11/14 , A61P25/04 , A61P39/00 , A61P43/00 , C07D489/12
CPC分类号： C07D489/12
摘要： The present invention provides compound having the structure: and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.
摘要翻译：本发明提供具有以下结构的化合物：及其药学上可接受的盐或衍生物，以及包含该化合物的组合物。本发明还提供了（1）预防疼痛，（2）治疗疼痛，（3）诱导镇静，（4）治疗阿片成瘾，（5）治疗鸦片戒断（戒断综合征）和/或（6）治疗咳嗽的方法通过施用本发明的化合物或组合物来治疗有此需要的患者。

6. 发明申请

WO2005011579A3 TREATMENT OF DEPENDENCE WITHDRAWAL 审中-公开
标题翻译：治疗依法撤销
公开(公告)号：WO2005011579A3
公开(公告)日：2005-06-09
申请号：PCT/US2004024010
申请日：2004-07-26
申请人： EURO CELTIQUE SA , REIDENBERG BRUCE E , SPYKER DANIEL A
发明人： REIDENBERG BRUCE E , SPYKER DANIEL A
IPC分类号： A61B19/00 , A61K20060101 , A61K9/70 , A61K31/485 , A61L15/00
CPC分类号： A61K9/7023 , A61K31/485 , A61L15/00 , B09B2220/14
摘要： Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
摘要翻译：描述了丁丙诺啡在怀孕的药物依赖性或阿片受体患者中治疗戒断或禁欲综合征的剂量方案。该方法包括通过透皮给药一定量的丁丙诺啡来治疗患者的戒断或禁欲综合征，所述丁丙诺啡有效地减少戒断症状。例如，可以在不超过约5天的第一给药期间施用第一种含丁丙诺啡的透皮剂型，第二给药期间不超过约5天的第二种含丁丙诺啡的透皮剂型，所述第二剂型包含与第一剂型相同或更高剂量的丁丙诺啡; 和含有至少2天的第三给药期的第三种含丁丙诺啡的透皮剂型，所述第三剂型包含与第二剂型相同或更高剂量的丁丙诺啡。

7. 发明申请

WO2004098567A3 TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER 审中-公开
标题翻译：包含活性剂代谢物组分和不利原料组分的防篡改剂量剂型在活性剂层的远距离位置
公开(公告)号：WO2004098567A3
公开(公告)日：2005-01-13
申请号：PCT/US2004013810
申请日：2004-04-30
申请人： PURDUE PHARMA LP , HOWARD STEPHEN A , REIDENBERG BRUCE
发明人： HOWARD STEPHEN A , REIDENBERG BRUCE
IPC分类号： A61K9/00 , A61K9/70 , A61K31/4468 , A61K31/485
CPC分类号： A61K9/7061 , A61K9/7092 , A61K31/4468 , A61K31/485
摘要： The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
摘要翻译：本发明包括透皮剂型，其包含活性剂组分，其包含活性剂和包含不利剂的不利剂组分，其中所述活性剂组分限定至少一个通过其延伸的通道。

8. 发明申请

WO2004054554A1 TRANSDERMAL BUPRENORPHINE TO TREAT PAIN IN SICKLE CELL CRISIS 审中-公开
标题翻译：转移性布地奈汀治疗小儿麻痹中的疼痛
公开(公告)号：WO2004054554A1
公开(公告)日：2004-07-01
申请号：PCT/US2003/039793
申请日：2003-12-15
申请人： EURO-CELTIQUE S.A. , REIDENBERG, Bruce, E. , SPYKER, Daniel, A.
发明人： REIDENBERG, Bruce, E. , SPYKER, Daniel, A.
IPC分类号： A61K9/70
CPC分类号： A61K45/06 , A61K9/7023 , A61K31/485
摘要： A specific dosage regimen of buprenorphine achieves pain relief from painful episodes due to sickle cell disease. The dosage regimen comprises administering to a patient in need of pain relief from sickle cell disease at least one BTDS transdermal patch. Alternatively, the dosing regimen comprises administering to the patient (1) a first buprenorphine-containing transdermal dosage form for a first dosing period; (2) administering to the patient a second buprenorphine-containing transdermal dosage form for a second dosing period, where the second dosage form comprises the same dosage of buprenorphine as, or a greater dosage of buprenorphine than, the first dosage form; and (3) administering to the patient a third buprenorphinecontaining transdermal dosage form for a third dosing period, where the third dosage form comprises a greater dosage of buprenorphine than the second dosage form.
摘要翻译：丁丙诺啡的具体给药方案由于镰状细胞病导致疼痛缓解。剂量方案包括向需要减轻镰状细胞病疼痛的患者施用至少一种BTDS透皮贴剂。或者，给药方案包括给予患者（1）第一给药期的第一种含丁丙诺啡的透皮剂型; （2）向患者施用第二给药期的第二种含有丁丙诺啡的透皮剂型，其中第二剂型包含与第一剂型相同的丁丙诺啡剂量或更大剂量的丁丙诺啡; 和（3）向患者施用第三次给药的透皮剂型，其中第三剂量形式包含比第二剂型更大剂量的丁丙诺啡。

9. 发明申请

WO2004017941A3 TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT AND A SALT AND FREE-BASEFORM OF AN ANTAGONIST 审中-公开
标题翻译：包含活性剂和拮抗剂的盐和自由基的透皮剂型
公开(公告)号：WO2004017941A3
公开(公告)日：2004-04-22
申请号：PCT/US0326132
申请日：2003-08-20
申请人： EURO CELTIQUE SA , SHEVCHUK IHOR , REIDENBERG BRUCE
发明人： SHEVCHUK IHOR , REIDENBERG BRUCE
IPC分类号： A61K9/70 , A61K31/445 , A61K31/4468 , A61K31/485 , A61K45/06 , A61P25/36
CPC分类号： A61K9/7069 , A61K9/7084 , A61K9/7092 , A61K31/445 , A61K31/4468 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent, such as an opioid antagonist, and a pharmaceutically acceptable salt of an adverse agent, such as an opioid antagonist. The transdermal dosage form allows an effective amount of the active agent, or a pharmaceutically acceptable salt thereof, to be transdermally administered to an animal. The invention further relates to methods for treating or preventing pain in an animal comprising contacting the skin of an animal in need thereof with the transdermal dosage form of the invention for an amount of time sufficient to treat or prevent pain.
摘要翻译：本发明涉及抗篡改透皮剂型，其包含活性剂如阿片样物质或其药学上可接受的盐，不利剂的游离碱如阿片样物质拮抗剂和不利的药学上可接受的盐剂，如阿片拮抗剂。透皮剂型允许将有效量的活性剂或其药学上可接受的盐透皮给药至动物。本发明进一步涉及治疗或预防动物疼痛的方法，其包括使有需要的动物的皮肤与本发明的经皮剂型接触足以治疗或预防疼痛的时间量。

10. 发明申请

WO2005007218A2 EX VIVO PERFUSION 审中-公开
公开(公告)号：WO2005007218A2
公开(公告)日：2005-01-27
申请号：PCT/US2004/022249
申请日：2004-07-09
申请人： EURO-CELTIQUE S.A. , REIDENBERG, Bruce, E. , BURCH, Ronald, M.
发明人： REIDENBERG, Bruce, E. , BURCH, Ronald, M.
IPC分类号： A61M
CPC分类号： A61M1/3679
摘要： A method of removing a target molecule from blood by contacting the blood with an ex vivo perfusion device comprising binding partners for the target molecule is provided. The ex vivo perfusion device preferably comprises one or more immobilized synthebodies as binding partners. Also provided is a method for treating a patient suffering from symptoms associated with an adenoma or other endocrine tumor. The method comprises contacting the blood or a blood component of the patient with an ex vivo perfusion device to which one or more binding partners of a hormone secreted by the tumor are immobilized. The tumor can be, for example, an insulinoma or a parathyroid hormone (PTH) adenoma, and the hormone can be, for example, insulin, PTH, glucagon, VIP, and somatostatin. The binding partner can be, e.g., a synthebody or a part thereof.
摘要翻译：提供了通过使血液与包含靶分子的结合配偶体的离体灌注装置接触来从血液中除去靶分子的方法。离体灌注装置优选包含一个或多个固定化合成物作为结合配偶体。还提供了治疗患有与腺瘤或其他内分泌肿瘤相关的症状的患者的方法。该方法包括使患者的血液或血液成分与体外灌注装置接触，所述离体灌注装置固定有一种或多种由肿瘤分泌的激素的结合配偶体。肿瘤可以是例如胰岛素瘤或甲状旁腺激素（PTH）腺瘤，并且该激素可以是例如胰岛素，PTH，胰高血糖素，VIP和生长抑素。结合配偶体可以是例如合成物或其一部分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式